{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:11:13Z","timestamp":1768003873771,"version":"3.49.0"},"reference-count":146,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The landscape of available therapeutic options for treatment of genitourinary (GU) cancers is expanding dramatically. Many of these treatments have distinct, sometimes severe, skin toxicities including morbilliform, bullous, pustular, lichenoid, eczematous, psoriasiform, and palmoplantar eruptions. Pruritus and skin pigmentation changes have also been noted. This review aims to synthesize dermatologic events observed with antibody drug conjugates, poly (ADP-ribose) polymerase (PARP) inhibitors, androgen receptor pathway inhibitors, tyrosine kinase inhibitors, immune checkpoint inhibitors, and the combination of these agents used for the treatment of GU cancers. It provides a guide on diagnosis and initial management of these rashes for medical oncologists.<\/jats:p>","DOI":"10.3390\/cancers17020251","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T06:13:07Z","timestamp":1736835187000},"page":"251","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnosis and Management of Skin Toxicities in Systemic Treatment of Genitourinary Cancers"],"prefix":"10.3390","volume":"17","author":[{"given":"Deepro","family":"Chowdhury","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"},{"name":"Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3640-1282","authenticated-orcid":false,"given":"Laura","family":"Chin","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roupen","family":"Odabashian","sequence":"additional","affiliation":[{"name":"Department of Oncology, Wayne State University, Detroit, MI 48202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Fawaz","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"},{"name":"Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Canil","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ong","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G.","family":"Kirchhof","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin. Neil","family":"Reaume","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4880-8167","authenticated-orcid":false,"given":"Ana-Alicia","family":"Beltran-Bless","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7651-0870","authenticated-orcid":false,"given":"Marie-France","family":"Savard","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Tsoulis","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2992-5632","authenticated-orcid":false,"given":"Dominick","family":"Boss\u00e9","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"ref_1","unstructured":"(2024, October 12). FDA Adverse Reporting Sytem (FAERS) Public Dashboard, Available online: https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/33a0f68e-845c-48e2-bc81-8141c6aaf772\/state\/analysis."},{"key":"ref_2","unstructured":"Bolognia, J.L., and Schaffer, J.C.L. (2018). Erythemas and Purpuras: Drug Reactions. Dermatology, Elsevier."},{"key":"ref_3","unstructured":"McAleer, M., and Irvine, A. (2018). Papulosquamous and Eczematous Dermatoses: Atopic Dermatitis. Dermatology, Elsevier."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Psoriasis 1: Pathogenesis and Clinical Features of Psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Watanabe, T., and Yamaguchi, Y. (2023). Cutaneous Manifestations Associated with Immune Checkpoint Inhibitors. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1071983"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2013.06.038","article-title":"Pruritus in Patients Treated with Targeted Cancer Therapies: Systematic Review and Meta-Analysis","volume":"69","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.det.2018.02.010","article-title":"Pruritus Associated with Targeted Anticancer Therapies and Their Management","volume":"36","author":"Wu","year":"2018","journal-title":"Dermatol. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/fcp.12558","article-title":"Drug-Induced Vitiligo: A Case\/Non-Case Study in Vigibase\u00ae, the WHO Pharmacovigilance Database","volume":"34","author":"Anthony","year":"2020","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune Checkpoint Inhibitor-Related Dermatologic Adverse Events","volume":"83","author":"Geisler","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","article-title":"Vitiligo: A Comprehensive Overview Part I. Introduction, Epidemiology, Quality of Life, Diagnosis, Differential Diagnosis, Associations, Histopathology, Etiology, and Work-Up","volume":"65","author":"Alikhan","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","first-page":"652","article-title":"The Hand-Foot-Syndrome Associated with Medical Tumor Therapy\u2014Classification and Management","volume":"8","author":"Degen","year":"2010","journal-title":"J. Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-Induced Hand-Foot Syndrome and Nail Changes: A Review of Clinical Presentation, Etiology, Pathogenesis, and Management","volume":"71","author":"Miller","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous Immune-Related Adverse Events (IrAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_15","first-page":"36","article-title":"Mild Cutaneous Reactions to Drugs","volume":"90","author":"Crisafulli","year":"2019","journal-title":"Acta Biomed."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.073","article-title":"Drug-Induced Hypersensitivity Syndrome\/Drug Reaction with Eosinophilia and Systemic Symptoms. Part II Diagnosis and Management","volume":"90","author":"Wei","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaad.2023.02.072","article-title":"Drug-Induced Hypersensitivity Syndrome\/Drug Reaction with Eosinophilia and Systemic Symptoms. Part I. Epidemiology, Pathogenesis, Clinicopathological Features, and Prognosis","volume":"90","author":"Wei","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Calle, A.M., Aguirre, N., Ardila, J.C., and Cardona Villa, R. (2023). DRESS Syndrome: A Literature Review and Treatment Algorithm. World Allergy Organ. J., 16.","DOI":"10.1016\/j.waojou.2022.100673"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-like Reactions to Checkpoint Inhibitors: A Systematic Review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/ijd.16572","article-title":"Successful Rechallenge with Pembrolizumab after Case of Progressive Immunotherapy-Related Mucocutaneous Eruption (PIRME), a Stevens-Johnson Syndrome-like Reaction","volume":"62","author":"Shi","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jaad.2020.03.029","article-title":"Generalized Bullous Mucocutaneous Eruption Mimicking Stevens-Johnson Syndrome in the Setting of Immune Checkpoint Inhibition: A Multicenter Case Series","volume":"83","author":"Molina","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe Cutaneous Adverse Reactions Induced by Targeted Anticancer Therapies and Immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hasegawa, A., and Abe, R. (2020). Recent Advances in Managing and Understanding Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. F1000Research, 9.","DOI":"10.12688\/f1000research.24748.1"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tsiogka, A., Bauer, J.W., and Patsatsi, A. (2021). Bullous Pemphigoid Associated with Anti-Programmed Cell Death Protein 1 and Anti-Programmed Cell Death Ligand 1 Therapy: A Review of the Literature. Acta Derm. Venereol., 101.","DOI":"10.2340\/00015555-3740"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Verheyden, M.J., Bilgic, A., and Murrell, D.F. (2020). A Systematic Review of Drug-Induced Pemphigoid. Acta Derm. Venereol., 100.","DOI":"10.2340\/00015555-3457"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jaad.2015.07.017","article-title":"Acute Generalized Exanthematous Pustulosis (AGEP): A Review and Update","volume":"73","author":"Szatkowski","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/bjd.13540","article-title":"Acute Generalized Exanthematous Pustulosis: A Retrospective Audit of Practice between 1994 and 2011 at a Single Centre","volume":"172","author":"Hotz","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/jdv.18879","article-title":"Cutaneous Lichenoid Drug Eruptions: A Narrative Review Evaluating Demographics, Clinical Features and Culprit Medications","volume":"37","author":"Maul","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"Am. J. Dermatopathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/ijd.ijd_878_23","article-title":"Clinical Profile of Patients with Lichenoid Drug Eruption: A Observational Study","volume":"69","author":"Bhanja","year":"2024","journal-title":"Indian J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic Toxicities to Immune Checkpoint Inhibitor Therapy: A Review of Histopathologic Features","volume":"83","author":"Ellis","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cutroneo, P., Ingrasciotta, Y., Isgr\u00f2, V., Rullo, E.V., Berretta, M., Fiorica, F., Trifir\u00f2, G., and Guarneri, C. (2021). Psoriasis and Psoriasiform Reactions Secondary to Immune Checkpoint Inhibitors. Dermatol. Ther., 34.","DOI":"10.1111\/dth.14830"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/15569527.2022.2034842","article-title":"Adverse Cutaneous Toxicities by PD-1\/PD-L1 Immune Checkpoint Inhibitors: Pathogenesis, Treatment, and Surveillance","volume":"41","author":"Bhardwaj","year":"2022","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14740338.2021.1915279","article-title":"Vitiligo Induced by Immune Checkpoint Inhibitors in Melanoma Patients: An Expert Opinion","volume":"20","author":"Lommerts","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ramondetta, A., Ribero, S., Conti, L., Fava, P., Marra, E., Broganelli, P., Caliendo, V., Picciotto, F., Guida, M., and Fierro, M.T. (2020). Clinical and Pathological Relevance of Drug-Induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF\/MEK Inhibitors. Acta Derm. Venereol., 100.","DOI":"10.2340\/00015555-3319"},{"key":"ref_37","first-page":"8655","article-title":"Prophylactic Strategies for Hand-Foot Syndrome\/Skin Reaction Associated with Systemic Cancer Treatment: A Meta-Analysis of Randomized Controlled Trials","volume":"30","author":"Pandy","year":"2022","journal-title":"Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"ref_38","first-page":"e447","article-title":"Immunotherapy-Induced Eczema Treated with Dupilumab","volume":"38","author":"Fidanzi","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","article-title":"Guidelines of Care for the Management of Atopic Dermatitis in Adults with Topical Therapies","volume":"89","author":"Sidbury","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of Care for the Management of Atopic Dermatitis in Adults with Phototherapy and Systemic Therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Kuo, A.M.-S., Gu, S., Stoll, J., Moy, A.P., Dusza, S.W., Gordon, A., Haliasos, E.C., Janjigian, Y., Kraehenbuehl, L., and Quigley, E.A. (2023). Management of Immune-Related Cutaneous Adverse Events with Dupilumab. J. Immunother. Cancer, 11.","DOI":"10.1136\/jitc-2023-007324"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_43","unstructured":"Seagen Inc. (2021). Product Monograph Including Patient Medication Information: PADCEV, Seagen Inc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2023.41.6_suppl.439","article-title":"Enfortumab Vedotin with or Without Pembrolizumab in Cisplatin-Ineligible Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer","volume":"41","author":"Milowsky","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_46","unstructured":"Seagen Inc. (2024, October 11). Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04223856?tab=results."},{"key":"ref_47","unstructured":"Bristol-Myers Squibb (2024, October 11). Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01668784?tab=results."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_50","unstructured":"Pfizer (2024, October 11). A Study of Avelumab in Patients with Locally Advanced or Metastatic Urothelial Cancer (JAVELIN Bladder 100). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02603432?tab=results."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_52","unstructured":"Bristol-Myers Squibb (2024, October 11). Nivolumab Combined with Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02231749?tab=results."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_54","unstructured":"Aragon Pharmaceuticals Inc. (2024, October 11). A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN). Clincal Trials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01946204?tab=results."},{"key":"ref_55","unstructured":"Aragon Pharmaceuticals Inc. (2024, October 11). A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants with mHSPC (TITAN). ClinicalTrials.Gov, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT02489318?tab=results."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide Treatment and Metastasis-Free Survival in Prostate Cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_59","unstructured":"Pfizer (2024, October 11). Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients with Nonmetastatic Prostate Cancer (EMBARK). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02319837?tab=results."},{"key":"ref_60","unstructured":"Pfizer Inc. (2024, October 11). A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients with Progressive Metastatic Prostate Cancer (PREVAIL). Clincal Trials.gov, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT01212991?tab=results."},{"key":"ref_61","unstructured":"Pfizer Inc. (2024, October 11). Safety and Efficacy Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02003924?tab=results."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in Metastatic Prostate Cancer before Chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_65","unstructured":"Pfizer Inc. (2024, October 11). Safety and Efficacy Study of MDV3100 in Patients with Castration-Resistant Prostate Cancer Who Have Been Previously Treated with Docetaxel-based Chemotherapy (AFFIRM). ClinicalTrials.Gov, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT00974311?tab=results."},{"key":"ref_66","unstructured":"Bayer Inc. (2024, October 11). Efficacy and Safety Study of Darolutamide (ODM-201) in Men with High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02200614?tab=results."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_68","unstructured":"Janssen Research & Development LLC. (2024, October 11). Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer. ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00887198?tab=results."},{"key":"ref_69","unstructured":"Janssen Research and Development LLC. (2024, October 11). A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants with High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01715285?tab=results."},{"key":"ref_70","unstructured":"Cougar Biotechnology Inc. (2024, October 11). Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy. ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00638690?tab=results."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","volume":"364","author":"Logothetis","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone Acetate plus Prednisone in Patients with Newly Diagnosed High-Risk Metastatic Castration-Sensitive Prostate Cancer (LATITUDE): Final Overall Survival Analysis of a Randomised, Double-Blind, Phase 3 Trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_75","unstructured":"AstraZeneca (2024, October 11). Study of Olaparib (LynparzaTM) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer (PROfound Study). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02987543?tab=results."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Clarke, N.W., Armstrong, A.J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., Procopio, G., de Menezes, J., Girotto, G., and Arslan, C. (2022). Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid., 1.","DOI":"10.1056\/EVIDoa2200043"},{"key":"ref_78","unstructured":"AstraZeneca (2024, October 11). Study on Olaparib Plus Abiraterone as First-Line Therapy in Men with Metastatic Castration-resistant Prostate Cancer. ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03732820?tab=results."},{"key":"ref_79","unstructured":"pharmaand GmbH (2024, October 11). A Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02952534?tab=results."},{"key":"ref_80","unstructured":"pharmaand GmbH (2024, October 11). A Study of Rucaparib Versus Physician\u2019s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02975934?tab=results."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in Men with Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or Physician\u2019s Choice in Metastatic Prostate Cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_83","unstructured":"Janssen Research & Development LLC. (2024, October 11). A Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants with Metastatic Prostate Cancer (MAGNITUDE). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03748641?tab=results."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_85","unstructured":"Pfizer (2024, October 11). Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2). ClincalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03395197?tab=results."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus Enzalutamide in Men with First-Line Metastatic Castration-Resistant Prostate Cancer (TALAPRO-2): A Randomised, Placebo-Controlled, Phase 3 Trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"ref_87","unstructured":"Bristol-Myers Squibb (2024, October 11). A Study of Nivolumab Combined with Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03141177?tab=results."},{"key":"ref_88","unstructured":"Eisai Inc (2024, October 11). Lenvatinib\/Everolimus or Lenvatinib\/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (CLEAR). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02811861?tab=results."},{"key":"ref_89","unstructured":"Novartis Pharmaceuticals (2024, October 11). Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and\/or Metastatic Renal Cell Carcinoma (COMPARZ). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00720941?tab=results."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus Cabozantinib versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma after Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"ref_95","unstructured":"Hoffmann-La Roche (2024, October 11). A Study of Atezolizumab in Combination with Cabozantinib Compared to Cabozantinib Alone in Participants with Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04338269?tab=results."},{"key":"ref_96","unstructured":"Exelixis (2024, October 11). A Study of Cabozantinib (XL184) vs. Everolimus in Subjects with Metastatic Renal Cell Carcinoma (METEOR). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01865747?tab=results."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus Sorafenib in Patients with Advanced Renal Cell Carcinoma (TIVO-3): A Phase 3, Multicentre, Randomised, Controlled, Open-Label Study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet. Oncol."},{"key":"ref_99","unstructured":"AVEO Pharmaceuticals, Inc. (2024, October 11). A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants with Refractory Advanced Renal Cell Carcinoma (RCC). Clincal Trials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02627963?tab=results."},{"key":"ref_100","unstructured":"Janssen Research & Development LLC. (2024, October 11). A Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Participants with Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR). Clincal Trials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03390504?tab=results."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_103","unstructured":"IPeloton Therapeutics, Inc. (2024, October 11). A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004). Clincal Trials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03401788?tab=results."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel\u2013Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_105","unstructured":"Merck Sharp, and Dohme LLC. (2024, October 11). Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib Versus Sunitinib Monotherapy in Participants with Renal Cell Carcinoma (MK-3475-426\/KEYNOTE-426). ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02853331?tab=results."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Kuo, A.M., and Markova, A. (2022). High Grade Dermatologic Adverse Events Associated with Immune Checkpoint Blockade for Cancer. Front. Med., 9.","DOI":"10.3389\/fmed.2022.898790"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma: Final Results and Analysis of Prognostic Factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"ref_109","unstructured":"Novartis Pharmaceuticals (2024, October 11). RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients with Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment with Sorafenib and\/or Sunitinib (RECORD-1). Clincal Trials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00410124?tab=results."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma (METEOR): Final Results from a Randomised, Open-Label, Phase 3 Trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet. Oncol."},{"key":"ref_111","unstructured":"U.S. Department of Health and Human Services (2017). Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. Cancer Ther. Eval. Progr., 155, 875\u2013888."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Fu, Z., Li, S., Han, S., Shi, C., and Zhang, Y. (2022). Antibody Drug Conjugate: The \u201cBiological Missile\u201d for Targeted Cancer Therapy. Signal Transduct. Target. Ther., 7.","DOI":"10.1038\/s41392-022-00947-7"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of Dermatologic Events Associated with the Nectin-4-Directed Antibody-Drug Conjugate Enfortumab Vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2022.02.019","article-title":"Life-Threatening Skin Reaction with Enfortumab Vedotin: Six Cases","volume":"167","author":"Guerrois","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Yang, H., Yu, X., and An, Z. (2021). Cutaneous Toxicity Associated with Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.801199"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Oh, Y., Bang, A., Kurtansky, N., Khan, N., Pulitzer, M., and Noor, S. (2021). Dermatologic Adverse Events of Brentuximab Vedotin: Characteristics, Management, and Their Relationship with Dose Regimen. J. Clin. Oncol., 39.","DOI":"10.1200\/JCO.2021.39.15_suppl.3049"},{"key":"ref_117","first-page":"355","article-title":"Extensive Toxic Epidermal Necrolysis Following Brentuximab Vedotin Administration","volume":"94","author":"Sconocchia","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1111\/ijd.15420","article-title":"Apalutamide-Induced Exanthematous Drug Eruption Displaying Spongiotic Dermatitis Successfully Treated with Dose Reduction","volume":"60","author":"Kawakami","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1111\/jdv.17657","article-title":"Maculopapular-Type Drug Eruptions Caused by Apalutamide: Case Series and a Review of the Literature","volume":"36","author":"Shima","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cia2.12138","article-title":"A Case of Toxic Epidermal Necrolysis Associated with Apalutamide Administration","volume":"3","author":"Sagawa","year":"2020","journal-title":"J. Cutan. Immunol. Allergy"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1111\/1346-8138.15510","article-title":"Fatal Case of Toxic Epidermal Necrolysis Due to Apalutamide Used as a Novel Prostate Cancer Drug","volume":"47","author":"Endo","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/JU.0000000000002425","article-title":"Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide","volume":"207","author":"Pan","year":"2022","journal-title":"J. Urol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Shore, N., Hafron, J., Saltzstein, D., Bhaumik, A., Aggarwal, P., Phillips, J., and McGowan, T. (2024). Impact of a Rash Management Guide in Patients Receiving Apalutamide for High-Risk Localized Prostate Cancer in the Apa-RP Study. Prostate Cancer Prostatic Dis.","DOI":"10.1038\/s41391-024-00858-4"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3315\/jdcr.2016.1226","article-title":"Enzalutamide Induced Acute Generalized Exanthematous Pustulosis","volume":"10","author":"Alberto","year":"2016","journal-title":"J. Dermatol. Case Rep."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Deng, M., Chai, H., Yang, M., Wei, X., Zhang, W., Wang, X., Li, J., Wang, Z., and Chen, H. (2021). Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.736975"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Gallegos, J.A.O., and Amar, S. (2021). Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis Overlap Caused by Enzalutamide in Patient with Metastatic Prostate Cancer. BMJ Case Rep., 14.","DOI":"10.1136\/bcr-2021-242319"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus Prednisone Added to Androgen Deprivation Therapy and Docetaxel in de Novo Metastatic Castration-Sensitive Prostate Cancer (PEACE-1): A Multicentre, Open-Label, Randomised, Phase 3 Study with a 2 \u00d7 2 Factorial Design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/1758834016656493","article-title":"Safety of Long-Term Exposure to Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer and Concomitant Cardiovascular Risk Factors","volume":"8","author":"Verzoni","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1245\/s10434-019-08183-0","article-title":"Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon","volume":"27","author":"Helmink","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_132","unstructured":"Forbes, L., Crespo, A., and Abella , L. (2024, October 11). Immune Checkpoint Inhibitor Toxicity Management Clinical Practice Guideline. Available online: https:\/\/www.cancercareontario.ca\/en\/guidelines-advice\/types-of-cancer\/52976."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal Cell Carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejcsup.2013.07.016","article-title":"Understanding and Managing Toxicities of Vascular Endothelial Growth Factor (VEGF) Inhibitors","volume":"11","author":"Schmidinger","year":"2013","journal-title":"EJC Suppl. Eur. J. Cancer Suppl."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Kwakman, J.J.M., Elshot, Y.S., Punt, C.J.A., and Koopman, M. (2020). Management of Cytotoxic Chemotherapy-Induced Hand-Foot Syndrome. Oncol. Rev., 14.","DOI":"10.4081\/oncol.2020.442"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving Strategies for the Management of Hand\u2013Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","article-title":"Belzutifan plus Cabozantinib for Patients with Advanced Clear Cell Renal Cell Carcinoma Previously Treated with Immunotherapy: An Open-Label, Single-Arm, Phase 2 Study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaad.2024.06.037","article-title":"Characterization of Adverse Cutaneous Effects in the Setting of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Retrospective Review","volume":"91","author":"Malik","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaad.2024.03.029","article-title":"Dermatologic Toxicity Associated with Targeted and Immunotherapies in Stage-IV Non-Small Cell Lung Cancer Patients: A 14-Year Cohort","volume":"91","author":"Peng","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/jdv.19112","article-title":"Cutaneous Manifestations Induced by Check Point Inhibitors in 120 Melanoma Patients-The European MelSkinTox Study","volume":"37","author":"Cassecuel","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jaad.2019.12.031","article-title":"Cutaneous Eruptions from Ibrutinib Resembling Epidermal Growth Factor Receptor Inhibitor\u2013Induced Dermatologic Adverse Events","volume":"88","author":"Singer","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaad.2022.08.001","article-title":"A Retrospective Case Series of 20 Patients with Immunotherapy-Induced Bullous Pemphigoid with Emphasis on Management Outcomes","volume":"87","author":"Bur","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2024.07.1456","article-title":"Evaluation of Anticancer Therapy-Related Dermatologic Adverse Events: Insights from Food and Drug Administration\u2019s Adverse Event Reporting System Dataset","volume":"91","author":"Salah","year":"2024","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/251\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:28:32Z","timestamp":1759919312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":146,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17020251"],"URL":"https:\/\/doi.org\/10.3390\/cancers17020251","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]}}}